FDA Expands Durvalumab Label to Operable Lung Cancer

Published Date: 19 Aug 2024

PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

2.

investigating radiation oncology applications of artificial general intelligence.

3.

Risk of a second cancer after early breast cancer is low, say new findings

4.

FDA Expands Durvalumab Label to Operable Lung Cancer

5.

Drugmaker Pulls Trodelvy's Bladder Cancer Approval


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot